176 related articles for article (PubMed ID: 29333527)
1. Impact of Genetic Ancestry on Outcomes in ECOG-ACRIN-E5103.
Schneider BP; Shen F; Jiang G; O'Neill A; Radovich M; Li L; Gardner L; Lai D; Foroud T; Sparano JA; Sledge GW; Miller KD
JCO Precis Oncol; 2017; 2017():. PubMed ID: 29333527
[TBL] [Abstract][Full Text] [Related]
2. Impact of African ancestry on the relationship between body mass index and survival in an early-stage breast cancer trial (ECOG-ACRIN E5103).
Ballinger TJ; Jiang G; Shen F; Miller KD; Sledge GW; Schneider BP
Cancer; 2022 Jun; 128(11):2174-2181. PubMed ID: 35285940
[TBL] [Abstract][Full Text] [Related]
3. Cytochrome P450 Oxidoreductase (POR) Associated with Severe Paclitaxel-Induced Peripheral Neuropathy in Patients of European Ancestry from ECOG-ACRIN E5103.
Shen F; Jiang G; Philips S; Gardner L; Xue G; Cantor E; Ly RC; Osei W; Wu X; Dang C; Northfelt D; Skaar T; Miller KD; Sledge GW; Schneider BP
Clin Cancer Res; 2023 Jul; 29(13):2494-2500. PubMed ID: 37126018
[TBL] [Abstract][Full Text] [Related]
4. ECOG-ACRIN EAZ171: Prospective Validation Trial of Germline Predictors of Taxane-Induced Peripheral Neuropathy in Black Women With Early-Stage Breast Cancer.
Schneider BP; Zhao F; Ballinger TJ; Garcia SF; Shen F; Virani S; Cella D; Bales C; Jiang G; Hayes L; Miller N; Srinivasiah J; Stringer-Reasor EM; Chitalia A; Davis AA; Makower DF; Incorvati J; Simon MA; Mitchell EP; DeMichele A; Miller KD; Sparano JA; Wagner LI; Wolff AC
J Clin Oncol; 2024 Jun; ():JCO2400526. PubMed ID: 38828938
[TBL] [Abstract][Full Text] [Related]
5. Charcot-Marie-Tooth gene, SBF2, associated with taxane-induced peripheral neuropathy in African Americans.
Schneider BP; Lai D; Shen F; Jiang G; Radovich M; Li L; Gardner L; Miller KD; O'Neill A; Sparano JA; Xue G; Foroud T; Sledge GW
Oncotarget; 2016 Dec; 7(50):82244-82253. PubMed ID: 27732968
[TBL] [Abstract][Full Text] [Related]
6. Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199.
Schneider BP; Li L; Radovich M; Shen F; Miller KD; Flockhart DA; Jiang G; Vance G; Gardner L; Vatta M; Bai S; Lai D; Koller D; Zhao F; O'Neill A; Smith ML; Railey E; White C; Partridge A; Sparano J; Davidson NE; Foroud T; Sledge GW
Clin Cancer Res; 2015 Nov; 21(22):5082-5091. PubMed ID: 26138065
[TBL] [Abstract][Full Text] [Related]
7. Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103).
Miller KD; O'Neill A; Gradishar W; Hobday TJ; Goldstein LJ; Mayer IA; Bloom S; Brufsky AM; Tevaarwerk AJ; Sparano JA; Le-Lindqwister NA; Hendricks CB; Northfelt DW; Dang CT; Sledge GW
J Clin Oncol; 2018 Sep; 36(25):2621-2629. PubMed ID: 30040523
[TBL] [Abstract][Full Text] [Related]
8. Platinum-based chemotherapy for early triple-negative breast cancer.
Mason SR; Willson ML; Egger SJ; Beith J; Dear RF; Goodwin A
Cochrane Database Syst Rev; 2023 Sep; 9(9):CD014805. PubMed ID: 37681577
[TBL] [Abstract][Full Text] [Related]
9. Impact of platinum-based chemotherapy on the prognosis of early triple-negative breast cancer: a systematic review and meta-analysis.
Zhao F; Shen G; Dong Q; Xin Y; Huo X; Wang M; Liu Z; Zhao Y; Ren D; Xie Q; Liu Z; Li Z; Gao L; Du F; Zhao J
Clin Exp Med; 2023 Oct; 23(6):2025-2040. PubMed ID: 36422737
[TBL] [Abstract][Full Text] [Related]
10. Taxanes for adjuvant treatment of early breast cancer.
Willson ML; Burke L; Ferguson T; Ghersi D; Nowak AK; Wilcken N
Cochrane Database Syst Rev; 2019 Sep; 9(9):CD004421. PubMed ID: 31476253
[TBL] [Abstract][Full Text] [Related]
11. Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198).
Schneider BP; O'Neill A; Shen F; Sledge GW; Thor AD; Kahanic SP; Zander PJ; Davidson NE
Br J Cancer; 2015 Dec; 113(12):1651-7. PubMed ID: 26625004
[TBL] [Abstract][Full Text] [Related]
12. Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial.
Yu KD; Ye FG; He M; Fan L; Ma D; Mo M; Wu J; Liu GY; Di GH; Zeng XH; He PQ; Wu KJ; Hou YF; Wang J; Wang C; Zhuang ZG; Song CG; Lin XY; Toss A; Ricci F; Shen ZZ; Shao ZM
JAMA Oncol; 2020 Sep; 6(9):1390-1396. PubMed ID: 32789480
[TBL] [Abstract][Full Text] [Related]
13. Variants in the vitamin D pathway, serum levels of vitamin D, and estrogen receptor negative breast cancer among African-American women: a case-control study.
Yao S; Zirpoli G; Bovbjerg DH; Jandorf L; Hong CC; Zhao H; Sucheston LE; Tang L; Roberts M; Ciupak G; Davis W; Hwang H; Johnson CS; Trump DL; McCann SE; Ademuyiwa F; Pawlish KS; Bandera EV; Ambrosone CB
Breast Cancer Res; 2012 Apr; 14(2):R58. PubMed ID: 22480149
[TBL] [Abstract][Full Text] [Related]
14. Taxane-induced neuropathy: How serious is this problem for patients with early breast cancer?
Nicolae R; Uccellini A; Siderov J; Mellerick A; Wong V; Yeo B
Asia Pac J Clin Oncol; 2023 Apr; 19(2):e118-e127. PubMed ID: 35692105
[TBL] [Abstract][Full Text] [Related]
15. Dose-dense paclitaxel versus docetaxel following FEC as adjuvant chemotherapy in axillary node-positive early breast cancer: a multicenter randomized study of the Hellenic Oncology Research Group (HORG).
Saloustros E; Malamos N; Boukovinas I; Kakolyris S; Kouroussis C; Athanasiadis A; Ziras N; Kentepozidis N; Makrantonakis P; Polyzos A; Christophyllakis C; Georgoulias V; Mavroudis D
Breast Cancer Res Treat; 2014 Dec; 148(3):591-7. PubMed ID: 25399229
[TBL] [Abstract][Full Text] [Related]
16. Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
Tolaney SM; Guo H; Pernas S; Barry WT; Dillon DA; Ritterhouse L; Schneider BP; Shen F; Fuhrman K; Baltay M; Dang CT; Yardley DA; Moy B; Marcom PK; Albain KS; Rugo HS; Ellis MJ; Shapira I; Wolff AC; Carey LA; Overmoyer B; Partridge AH; Hudis CA; Krop IE; Burstein HJ; Winer EP
J Clin Oncol; 2019 Aug; 37(22):1868-1875. PubMed ID: 30939096
[TBL] [Abstract][Full Text] [Related]
17. Serum sodium ions and chloride ions associated with taxane-induced peripheral neuropathy in Chinese patients with early-stage breast cancer: A nation-wide multicenter study.
Zhai J; Sun X; Zhao F; Pan B; Li H; Lv Z; Cao M; Zhao J; Mo H; Ma F; Xu B
Breast; 2023 Feb; 67():36-45. PubMed ID: 36586272
[TBL] [Abstract][Full Text] [Related]
18. Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†.
von Minckwitz G; Loibl S; Untch M; Eidtmann H; Rezai M; Fasching PA; Tesch H; Eggemann H; Schrader I; Kittel K; Hanusch C; Huober J; Solbach C; Jackisch C; Kunz G; Blohmer JU; Hauschild M; Fehm T; Nekljudova V; Gerber B; ; Gnauert K; Heinrich B; Prätz T; Groh U; Tanzer H; Villena C; Tulusan A; Liedtke B; Blohmer JU; Kittel K; Mau C; Potenberg J; Schilling J; Just M; Weiss E; Bückner U; Wolfgarten M; Lorenz R; Doering G; Feidicker S; Krabisch P; Deichert U; Augustin D; Kunz G; Kast K; von Minckwitz G; Nestle-Krämling C; Rezai M; Höß C; Terhaag J; Fasching P; Staib P; Aktas B; Kühn T; Khandan F; Möbus V; Solbach C; Tesch H; Stickeler E; Heinrich G; Wagner H; Abdallah A; Dewitz T; Emons G; Belau A; Rethwisch V; Lantzsch T; Thomssen C; Mattner U; Nugent A; Müller V; Noesselt T; Holms F; Müller T; Deuker JU; Schrader I; Strumberg D; Uleer C; Solomayer E; Runnebaum I; Link H; Tomé O; Ulmer HU; Conrad B; Feisel-Schwickardi G; Eidtmann H; Schumacher C; Steinmetz T; Bauerfeind I; Kremers S; Langanke D; Kullmer U; Ober A; Fischer D; Kohls A; Weikel W; Bischoff J; Freese K; Schmidt M; Wiest W; Sütterlin M; Dietrich M; Grießhammer M; Burgmann DM; Hanusch C; Rack B; Salat C; Sattler D; Tio J; von Abel E; Christensen B; Burkamp U; Köhne CH; Meinerz W; Graßhoff ST; Decker T; Overkamp F; Thalmann I; Sallmann A; Beck T; Reimer T; Bartzke G; Deryal M; Weigel M; Huober J; Weder P; Steffens CC; Lemster S; Stefek A; Ruhland F; Hofmann M; Schuster J; Simon W; Kronawitter U; Clemens M; Fehm T; Janni W; Latos K; Bauer W; Roßmann A; Bauer L; Lampe D; Heyl V; Hoffmann G; Lorenz-Salehi F; Hackmann J; Schlag R
Ann Oncol; 2014 Dec; 25(12):2363-2372. PubMed ID: 25223482
[TBL] [Abstract][Full Text] [Related]
19. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer.
Yardley DA; Arrowsmith ER; Daniel BR; Eakle J; Brufsky A; Drosick DR; Kudrik F; Bosserman LD; Keaton MR; Goble SA; Bubis JA; Priego VM; Pendergrass K; Manalo Y; Bury M; Gravenor DS; Rodriguez GI; Inhorn RC; Young RR; Harwin WN; Silver C; Hainsworth JD; Burris HA
Breast Cancer Res Treat; 2017 Aug; 164(3):649-658. PubMed ID: 28508185
[TBL] [Abstract][Full Text] [Related]
20. Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study.
Watanabe T; Kuranami M; Inoue K; Masuda N; Aogi K; Ohno S; Iwata H; Mukai H; Uemura Y; Ohashi Y
Cancer; 2017 Mar; 123(5):759-768. PubMed ID: 28081304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
